Takara Bio's RetroNect Used in Australia for Gene Therapy Clinical Trials of Multiple Myeloma.Tokyo, Japan, Dec 18, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Takara Bio has entered into a license and material transfer agreement with the Peter MacCallum Cancer Centre in Melbourne, Australia to supply Takara Bio's RetroNectin for use in a phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I of multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility (MM), which is being conducted by the group of principal investigator Professor Miles Prince. Six patients are expected to be enrolled in this phase I trial. MM is a malignant hematological hematological, hematologic pertaining to or emanating from blood cells. hematological tests total and differential white cell counts, hematocrit estimation, erythrocyte count. disease of the body's antibody producing cells, which causes them to grow out of control in the bone marrow, resulting in severe symptoms such as dissolution of the surrounding bone, aberration of the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. , and renal damage. The yearly incidence of MM is approximately 2-3 per 100,000, with an increasing incidence in the elderly. The median survival of MM patients treated with standard dose chemotherapy is only about three years. This is the 41st clinical trial in which the RetroNectin method has been used, and is the first time the RetroNectin method has been used a clinical trial conducted outside Japan, Europe or the United States. Currently, ex vivo gene therapy is expanding throughout the world as an effective treatment method for several incurable diseases. As a result, the RetroNectin method is becoming recognized as an essential and standard technology for ex vivo gene therapy. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion